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Abstract: Background: While critical insights have been gained from evaluating the genomic landscape
of metastatic prostate cancer, utilizing this information to inform personalized treatment is in its
infancy. We performed a retrospective pilot study to assess the current impact of precision medicine
for locally advanced and metastatic prostate adenocarcinoma and evaluate how genomic data could
be harnessed to individualize treatment. Methods: Deep whole genome-sequencing was performed
on 16 tumour-blood pairs from 13 prostate cancer patients; whole genome optical mapping was
performed in a subset of 9 patients to further identify large structural variants. Tumour samples
were derived from prostate, lymph nodes, bone and brain. Results: Most samples had acquired
genomic alterations in multiple therapeutically relevant pathways, including DNA damage response
(11/13 cases), PI3K (7/13), MAPK (10/13) and Wnt (9/13). Five patients had somatic copy number
losses in genes that may indicate sensitivity to immunotherapy (LRP1B, CDK12, MLH1) and one
patient had germline and somatic BRCA2 alterations. Conclusions: Most cases, whether primary or
metastatic, harboured therapeutically relevant alterations, including those associated with PARP
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inhibitor sensitivity, immunotherapy sensitivity and resistance to androgen pathway targeting agents.
The observed intra-patient heterogeneity and presence of genomic alterations in multiple growth
pathways in individual cases suggests that a precision medicine model in prostate cancer needs
to simultaneously incorporate multiple pathway-targeting agents. Our whole genome approach
allowed for structural variant assessment in addition to the ability to rapidly reassess an individual’s
molecular landscape as knowledge of relevant biomarkers evolve. This retrospective oncological
assessment highlights the genomic complexity of prostate cancer and the potential impact of assessing
genomic data for an individual at any stage of the disease.
Keywords: prostate cancer; precision medicine; whole genome sequencing; optical mapping; therapy
1. Introduction
Worldwide, prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer in men
and a leading cause of cancer-related male deaths [1]. Treatment strategies range from observation
alone to multi-modal treatment and vary based on clinical and pathological factors such as tumour
stage (T Stage), prostate specific antigen (PSA) level, Gleason or International Society of Urological
Pathology (ISUP) score and life expectancy. PCa is a heterogeneous disease, and these clinical factors
alone cannot predict outcomes accurately. Early disease is potentially curable whereas eventual
treatment resistance is an intractable problem in metastatic disease. In both early and advanced disease,
escalation of treatment including combination therapies, such as androgen deprivation therapy (ADT)
administered with docetaxel with or without radiotherapy to the primary has resulted in improved
outcomes [2–5]. However, the escalated treatment comes at the cost of increased toxicity and only
a subset of men garner benefit. As such, predictive biomarkers for optimal treatment selection are
needed at all stages of the disease.
PCa progression is driven by genomic alterations and, as such, large sequencing efforts have focused
on elucidating the succession of events driving its pathogenesis and progression. These sequencing
efforts aim to establish new prognostic and therapeutic targets [6–11]. Thus far, these studies have
focused on primary tumours from localized cancers and/or heavily pre-treated disease that has become
resistant to ADT, termed castrate-resistant prostate cancer (CRPC). It has been established that intra-
and inter-patient heterogeneity is high [12–16], though certain critical events may occur early in
some patients and propagate. In general, genomic changes are thought to accumulate in response
to treatment as the disease progresses and the importance of structural variants (SVs) in advanced
prostate cancer is an evolving area of research [10,11].
A goal of previous studies is to advance “precision medicine” in PCa. Robinson et al. found that
89% of CRPC samples harboured a clinically actionable genomic alteration [6]. However, clinical trials
utilizing the precision medicine paradigm of selecting a targeted drug based on molecular criteria have
yielded mixed results. For example, though phosphoinositide 3-kinase (PI3K)/Protein Kinase B (Akt)
pathway activating alterations are commonly reported in PCa, PI3K inhibitors have demonstrated
limited efficacy to date [17,18]. However, a randomized phase II study of abiraterone +/−ipatasertib,
an Akt inhibitor, in metastatic CRPC did find improved antitumoral activity in the combination arm,
particularly in men with PTEN loss [19]. Similarly, poly ADP ribose polymerase (PARP) inhibitors
have shown promise in selected men with CRPC and homologous recombination deficiency [20–23]
but not all mutations in the homologous recombination pathway predict a response [21].
Although these large genomic studies have expanded the knowledge of molecular drivers of
treatment-naïve primary and metastatic CRPC, they have generally viewed the data as a cohort without
looking at cumulative alterations and their potential therapeutic impact within the individuals. Likewise,
hormone sensitive (HSPC) metastatic disease has also been largely neglected. In this study, we performed
whole genome sequencing (WGS) on men with confirmed PCa in order to assess the collective genomic
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events in individual cases and their impact on real-world therapeutic decisions. Recognizing the importance
of SVs in prostate cancer and the limitations of WGS in detecting large genomic rearrangements, we also
performed whole genome optical mapping (WGM) on a subset of the samples.
2. Results
2.1. Shared Genomic Landscape
In this study, we retrospectively analysed 13 PCa cases that had micro- or macro-metastatic disease
at the time of sampling for genomic interrogation. Patient clinical and pathological characteristics are
summarized in Table 1. Sixteen tumour samples comprised of nine primary and seven metastatic
biopsies and the sites of concurrent or subsequent metastases included: bone (seven cases), lymph nodes
(four cases), and brain (one case), while a single case had biochemically relapsed without evidence
of macro-metastatic disease on conventional imaging. Figure 1 summarizes the commonalities and
differences in the genomic landscape between our primary and metastatic samples, while placing our cases
in context with the current knowledge based on large PCa WGS efforts. For the latter, we focused on the
study published by Wedge et al. in 2018 for 112 patients (92 primary and 20 metastatic) with the metastases
evenly distributed between HSPC and CRPC and biased towards lymph node metastasis (15/20) [8].
Common predisposing germline variants (Table S1) in our samples include the EHBP1 rs721048
(c.1185 + 30064G > A) intronic variant in five (38%) andFGFR4 rs35185519011 (c.1162G > A, p.Gly388Arg)
in ten (77%) cases. Reported in 9% of the healthy population [24], the EHBP1 rs721048 A-allele has
been associated with a more aggressive PCa [25]. The functional variant in FGFR4, although present
in 30% of the healthy population, may predispose PCa patients to an accelerated disease course [26].
Ten patients had one of two SNPs (rs1859962, rs8072254) in non-coding regions of the 17q24.3 locus
previously associated with PCa susceptibility [27].
Common somatic alterations include ETS fusions (seven cases) and TP53 alterations (six cases).
Tumour mutational burden (TMB) was generally low, ranging from 0.73 to 5.79 mutations/Megabase
(mut/Mb) (IQR 1.30–2.09), and did not correlate with disease stage at sampling (Figure 1, Table S2).
Percent genome altered (PGA) ranged from 2.2% to 63.9% (IQR 2.79–19.4%) (Table S2).
We observed a prevalence (11/13 cases) of somatic copy number alterations (SCNA) affecting at
least one DNA damage response (DDR) pathway gene (Table S4). Losses in FANCA, which helps
recruit DNA repair proteins to areas of DNA damage [28], were present in five (38%) cases, while
one case harboured germline and somatic BRCA2 alterations. With variation depending on the gene
sets tested for and stage of disease, DDR gene alterations occur in approximately 20% of PCas with
BRCA2 alterations reported for 3% of prostatic and 12% of metastatic samples [6,7,29]. Aside from
DDR, the most commonly impacted pathways were Phosphoinositide 3-kinase (PI3K, 7/13 (54%)
cases), Mitogen-activated protein kinase (MAPK, 10 (77%) cases) and Wnt (9 (69%) cases) (Table 2).
PI3K and MAPK are intracellular and extracellular signalling pathways, respectively, that are key to the
regulation of the cell cycle and, like certain DDR pathways, are therapeutically targetable (manipulable)
with inhibitory drugs [30,31]. The Wnt signalling pathway is a cellular pathway involved in cell
growth, embryogenesis and cell cycle progression, the activation of which has been implicated in
progression to CRPC and treatment resistance [32]. Previous studies have found that approximately
25% of primary PCas harbour PI3K or MAPK pathway alterations while nearly 50% of metastatic
CRPC samples have PI3K alterations [6,7] and 32% MAPK amplifications [30]. In our study, 6 of the
7 samples with somatic alterations impacting PI3K were in the primary tissue, and MAPK alterations
were seen in 4/7 (57%) of the metastases and 6/8 (75%) of the primaries.
Overall, SCNAs and SVs, rather than single nucleotide variants (SNVs) and small insertions and
deletions (sequences of no more than 50 nucleotides in length, indels), were more commonly acquired
in PCa relevant genes (Tables S1–S6). The addition of WGM identified 120 SVs not identified by WGS
alone, several of which overlapped with oncogenic and/or tumour suppresser genes (Table 3, Table S6).
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In particular, large insertions and duplications were typically missed by our short-read WGS approach.
However, no recurrent WGM-derived SVs were observed across the cases.
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Met-HSPC: metastatic hormone sensitive PCa; met-CRPC: metastatic castration-resistant PCa; TMB: 
Tumour mutational burden; SNV: single nucleotide variants; Indel: small insertion or deletion; Gains 
and Losses: somatic copy number alterations (SCNA); SV: Structural variation including large 
insertions or deletions, inversions, translocations and duplications; PSA: prostate-specific antigen 
(ug/L); ETS: presence of ETS fusion event; TP53: presence of TP53 alteration including SNV, SCNA or 
SV; SPOP: presence of SPOP SNV; BCR: biochemical recurrence; ISUP: International Society of 
Urological Pathologists cancer grade (correlates to Gleason scores). Error bars for Wedge et al. data 
reflect +/− one standard deviation of the sub-group totals. Sample identifiers in red, with matching 
red bar plots, are indicative of patients pre-treated with ADT. 
Figure 1. Sum ar f e ic la scape relevant to tumour purity and related to clinical and
pathological features for 16 samples from 13 patients, and further compared to the Wedge et al.
data. Met-HSPC: metastatic hormone sensitive PCa; met-CRPC: metastatic castration-resistant PCa;
TMB: Tumour mutational burden; SNV: single nucleotide variants; Indel: small insertion or deletion;
Gains and Losses: somatic copy number alterations (SCNA); SV: Structural variation including large
insertions or deletions, inversions, translocations and duplications; PSA: prostate-specific antigen
(ug/L); ETS: presence of ETS fusion event; TP53: presence of TP53 alteration including SNV, SCNA
or SV; SPOP: presence of SPOP SNV; BCR: biochemical recurrence; ISUP: International Society of
Urological Pathologists cancer grade (correlates to Gleason scores). Error bars for Wedge et al. data
reflect +/− one standard deviation of the sub-group totals. Sample identifiers in red, with matching red
bar plots, are indicative of patients pre-treated with ADT.
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Recurrent non-coding events in key PCa-associated genes have been reported [8,11,33–37],
including transcription factor (TF) binding sites. Alterations at key non-coding sites within our cases
are summarised in Table 4. Common to CRPC, SCNAs or SVs upstream of the androgen receptor (AR)
gene were not seen in our cases, which is unsurprising given the hormone sensitive status of most of
our patients. All but two of our samples contained non-coding AR binding site mutations (Table 4).
Overall, 20% of the somatic SNVs or indels affected at least one TF binding cluster. However, no
sample was significantly enriched for mutations within TF binding clusters and no TFs were enriched
for mutations. Notably, 0.3% of the 10.5 million TF binding clusters analysed correspond to JUN, an
average of 1.2% (0.5–1.5%) of somatic SNV in JUN binding clusters. JUN is a transcription factor that
antagonizes AR signalling [38].
Excluding COSMIC Mutational Signature 1 common to all cancers, we observed a predominance
of Mutational Signatures 3 and/or 8 (Figure 2A) that generally reduced in proportion from the
clonal to subclonal stages of tumour evolution (Figure 2B). Known to be associated with DDR gene
alterations [39–41], Signature 8 was particularly common in the primary 8/9 (89%) versus metastatic
3/7 (43%) samples, with notable loss in both of case 19651’s lymph node metastases. In contrast,
Signature 5, which is seen in most cancer types, particularly in smokers [39], and Signature 16, most
often associated with liver cancer, both increased in the subclonal stage of tumour evolution.
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Table 1. Clinical and pathological characteristics.
Diagnosis Time of Sample Collection for Genomic Interrogation Relapse and Outcomes
Patient
ID Age Stage
Initial
Treatment ISUP
Clinical
State PSA ECOG Symptoms
Sample
Site
ADT
Prior CRPC?
Time to
BCR (mos)
Rx for
BCR
Time to
Mets (mos)
Duration
Follow-Up
(mos)
1135 64 T3N0 RP 3 Rl 80.7 1 Yes Bone Yes Yes 33 ADT 68 68
19651 63 T3N1 ADT, RP,aRT 4 Dx 28 0 No
Prostate,
nodes
Yes
(6wks) No NR NA NR 20
147 67 T2N0 RP 2 Rl 4.4 0 Yes Bone No No 84 Nil 107 135
19260 69 T3N1 RP 3 Dx 9.2 0 No Prostate No No 16 sRT NR 27
5545 58 T3N0 RP 4 Dx 6.3 0 No Prostate No No 6 sRT 24 72
5684 60 T3N0 RP 5 Dx 15.7 0 No Prostate No No 36 ADT 120 132
19145 69 T3N1 RP, aRT 4 Dx 20 0 No Prostate Yes(4wks) No NR NR NA 33
19011 66 T3N1 RP, aRT 5 Dx 8.9 0 No Prostate No No NR NA NA 35
12543 51 T4N0 RP, aRT 5 Dx 18.6 0 No Prostate No No 72 ADT NA 120
13179 59 T3N0 RP, aRT,ADT 5 Dx 8.4 0 No Prostate No No 51 ADT 51 51
PCSD13 69 TxNxM1 ADT - Dx 12.8 2 Yes Bone Yes(8wks) No NA NA NA 9
A153 71 T2N0 RP 3 Rl 1.5 0 Yes Bone No No 93 Nil 105 120
80002 77 TxNxM1 Resection,ADT 5 Dx - 1 Yes Brain No No NA NA NA 1
Dx = Diagnosis; Sample = time of tissue biopsy for genomic interrogation; ADT = Androgen deprivation therapy; RP = radical prostatectomy; aRT = adjuvant radiotherapy; sRT = salvage
radiotherapy; Rl = Relapse; ECOG = Eastern Cooperative Oncology Group Performance Status; wks: weeks; BCR = Biochemical relapse; mos = months; NR = Not relapsed;
NA = Not applicable.
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Table 2. Genomic alterations affecting key genes in the PI3K, MAPK and WNT signaling pathways.
PI3K Pathway MAPK Pathway WNT Pathway
Gene Cases Event Gene Cases Event Gene Cases Event
PTEN 554512543,1914519145 SNVSCNASV BRAF
1926019651LP, 13179,
1135, 147, A153,
8000219145,19651LP+RP,
80002
SNVSCNASV APC
19651LP, 5545,
A15319651LP+RP,
12543, 5545, A153
SCNASV
PIK3CA 19651LP, 13179 SCNA EGFR 13179, 80002 SCNA CTNNB1 19651LP, 13179 SCNA
PIK3CB 13179 SCNA KRAS 19145, 5545, 5684 SCNA RNF43 80002, 14780002, 147 SCNASV
PIK3R1 5684, 13179 SCNA MAP3K1 5684, 13179,A153,19651RP+LP SCNASV WNT5A
19651LP, 13179,
8000219260 SCNASV
AKT1 PCSD13 SNV, SCNA RAF1 19651LP, 13179, 147,80002 SCNA MED12 19011 Germline SNV
Table 3. Structural variants identified by optical mapping as compared to whole genome sequencing. INS: Insertion; DEL: deletion; DUP: duplication; INV: inversion;
Intra-Chr: intrachromosomal translocation; Inter-Chr: interchromosomal translocation.
Disease State of
Sample
Sample
ID
SVs from Whole Genome Optical Mapping % Missed by Whole Genome Sequencing
Total INS DEL DUP INV Intra-Chr Inter-Chr Total INS DEL DUP INV Intra-Chr Inter-Chr
Primary Tumor
5545 39 0 27 3 0 7 2 36 - 37 67 - 29 0
13179 2 0 2 0 0 0 0 100 - 100 - - - -
5684 5 3 2 0 0 0 0 100 100 100 - - - -
12543 10 1 5 0 0 1 3 60 0 40 - - 100 67
19651LP 91 5 33 3 1 19 30 29 60 39 0 0 11 27
Met HSPC
A153 8 6 1 1 0 0 0 100 100 100 100 - - -
147 5 4 0 1 0 0 0 100 100 - 100 - - -
19651LLN 10 0 10 0 0 0 0 100 - 100 - - - -
80002 70 2 25 13 1 9 20 54 50 52 100 100 56 25
MetCRPC 1135 6 2 4 0 0 0 0 100 100 100 - - - -
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Table 4. Sites of recurrent non-coding alterations reported in the literature with potential clinical relevance.
Nearby Gene Variant Positions Data from Literature Reference Patient IDs
NEAT1 Chr11:65,190,268-65,213,009
13/112 cases, 6/20 mets all with previous ADT.
NEAT1 produces a long non-coding RNA
that regulates several growth pathways and
overexpression is associated with PCa
progression
Wedge [8] 5545
FOXA1 Promoter, Chr14:37587200-37597201 14 coding and 6 non-coding mutations;regulates AR signalling Wedge 5684
FOXA1
Chr14:37886261-37888565,
37903630-37906634, 38035667-38036817,
38053354-38056060, 38056084-38059097,
38127358-38128083
FOXA1 is a co-factor for AR. These are
cis-regulatory elements Zhou [34] 5684
AR Upstream promoter Tandem duplications, 70–87% mCRPC vs.
<2% primary PCa Viswanathan [11] Nil
AR ChrX: 66117800-66128800 (66.10–66.20 bin)
I peak, long range enhancer of AR, only 1/54
primary samples (Viswanathan); Copy
number gain results in proliferation in low
androgen condition and enzalutamide
resistance
Takeda [35],
Viswanathan Nil
AR Transcription Factor Binding Sites Recurrently altered in primary PCa Morova [33]
1135, 5545, 5684, 12543, 13179,
19011, 19145, 19260, 80002, 19651
(LP, RP, RLN), A153, PCSD13
MYC Chr8: 128.14–128.28, 128.47–128.54,128.54–128.62
8q24 risk loci PCa, associated with MYC
enhancer activity
Ahmadiyeh [37],
Yeager [36] 19651LP, 12543, A153
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2.2. Primary Prostate Samples with Synchronous Lymph Node Metastases: 19011, 19260, 19145 and 19651
These cases each presented with elevated PSA levels and prostate adenocarcinomas confirmed
on biopsy. Only 19651 had evidence of nodal metastases on conventional imaging preoperatively.
However, at radical prostatectomy with lymph node dissection, all had pathologically involved nodes.
Genomic alterations of potential relevance are summarized in Figure 3 (19011, 19260, 19145) and
Figure 4 (19651). Though nodal involvement at presentation is associated with a high PCa mortality
rate [42], the optimal management strategy for these men has not been established. Retrospective
data suggest that adjuvant ADT with radiotherapy compared to ADT or observation is beneficial for
men with lymph node metastases identified at radical prostatectomy [43]. Based on their ISUP grade
group or Gleason score and tumour (T) stage, 19011, 19145 and 19651 also meet eligibility criteria
for the STAMPEDE trial arms C and G that have shown benefit for adding docetaxel or abiraterone
respectively to ADT [3,44,45]. Though some studies of men with high-risk localized PCa treated with
neoadjuvant and/or adjuvant docetaxel demonstrate improved outcomes, these improvements occur
in a small proportion, with significant toxicity to many [4,46,47]. These studies have all been based on
clinical risk factors, thus, there is an urgent need for biomarkers that better select men likely to benefit,
thereby avoiding over- and undertreatment.
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Figure 3. Summary of genomic alterations in primary prostate samples with synchronous lymph node
metastases (Cases 19011, 19260 and 19145). Relevant somatic variants by type listed with SCNAs:
blue indicates loss. Circos plots depict mutational load in each tumour sample. The outermost (first)
track: autosome (chromosomes 1 to Y) ideograms with centromeres shown in red and the pter-qter
orientation in a clockwise direction (length in Mbp); second track: somatic copy-number gains (red)
and losses (blue); third track: somatic SNV allele frequencies (not corrected for tumour purity) coloured
according to their mutation changes per Alexandrov et al. [39]; fourth and fifth tracks: allele frequencies
(not corrected for tumour purity) of small deletions (red) and insertions (blue); innermost circle:
acquired genomic rearrangements, including deletions (blue), tandem duplications (red), inversions
(orange), insertions (black) and interchromosomal translocations (grey). MET: metastases.
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2.2.1. Case 19011: Left Prostate Tumour Core Biopsy
This TMPRSS2-ERG positive case had a somatic missense mutation in MED12 (c.3670C > G;
p.Leu1224Val), that is potentially pathogenic in many cancers, including prostate [48], via its
upregulation of Wnt/β-catenin signalling [49]. A non-coding somatic SNV upstream of CTNNB1 that is
within the binding region of 188 TFs, may indicate misregulation of this gene involved in Wnt/β-catenin
signalling [50]. No therapeutically relevant SCNA or SV was identified. PGA was low (2.7%).
Although no targetable alteration is seen in this case, the lack of mutations and low PGA may
still be valuable in guiding decision-making. This patient is unlikely to respond to targeted therapies,
like P RP inhibitors, but also to non-targeted agents that rely upon high mutational loads, such as
immune checkpoint inhibition. The lack of poor prognostic markers, such as TP53 loss, could mean this
low volume, locally advanced PCa may respond well to aggressive local therapy without escalation
to systemic therapy (e.g., addition of docetaxel). A low PGA is associated with a lower risk of BCR
following definitive local therapy [51]. Despite meeting criteria for perioperative therapy trials, his
genomic profile suggests aggressive local therapy will be sufficient. However, should he relapse
however, the alterations in Wnt pathway-associated regions could confer resistance to AR targeting
agents [32].
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2.2.2. Case 19260: Right Prostate Tumour Core Biopsy
Patient 19260 was also treatment-naïve at the time of his prostatectomy and sampling for WGS.
He biochemically relapsed 16 months postoperatively at which time he had salvage radiotherapy with
a good PSA response.
TMPRSS2-ERG fusion positive with a low PGA (2.4%), this case presented with a pathogenic
somatic missense mutation in BRAF (c1406G > T; p.Gly469Val). Known to confer increased kinase
activity [48], this mutation may sensitise the patient to BRAF +/−MEK inhibitor therapy. Of interest in
CRPC [30], with a report of response to targeted therapy in a BRAF mutant patient [52], clinical trials of
MEK inhibitors are currently underway (NCT02881242). Though not relevant to this patient’s upfront
treatment, it could prove useful in the event of relapse.
2.2.3. Case 19145: Left Prostate Tumour Core Biopsy
This TMPRSS2-ERG positive tumour had a high PGA (10.2%), but lacked any known deleterious
somatic mutation. SCNAs/SVs of note include heterozygous losses in PTEN, FANCA, CDK12, TP53,
NCOR1 and NCOR2, an inter-chromosomal translocation with breakpoints overlapping RAD51B and
PTEN and a large heterozygous deletion overlapping with TP53 and NCOR1.
Responses to PARP inhibition have been seen in patients with FANCA alterations [23,53] and
preclinical data suggest that PTEN loss sensitises cancers to PARP inhibitors, with reported cases of
exceptional responses to olaparib [54,55]. However, resistance to single agent PARP inhibition has
been described in Pten/p53 deficient mouse models, though a synergistic response was seen upon
PARP inhibition in combination with PI3K inhibition. [56]. NCOR1 and NCOR2 are transcriptional
corepressors that negatively regulate androgen receptor (AR) signalling and androgen-induced cell
proliferation [57–59]; losses in these genes increase with disease progression and are associated with
anti-androgen and ADT resistance [60,61]. TP53 loss may also predict inferior responses to novel
androgen signalling inhibitors (ASIs), such as enzalutamide and abiraterone, in CRPC [62]. CDK12
loss may predict sensitivity to immune checkpoint inhibiting therapies [63].
Many of the observed alterations in this case have therapeutic potential but are still the subject of
early phase clinical trials. The presence of the NCOR1/2 losses, however, may indicate a vulnerability
in this patient for early development of CRPC. His four week course of ADT preoperatively may have
induced treatment resistant clones even at this early stage. These losses together with TP53 loss and
high PGA indicate this patient may develop early resistance to ADT and, given his high-risk disease at
presentation, he would be an ideal candidate for escalation of his initial treatment with chemotherapy.
2.2.4. Case 19651: Bilateral Prostate and Internal Iliac Node Tumour Core Biopsies
Reporting a family history of PCa, via his father, and breast cancer in his mother and sister, it was
not surprising that this patient carries a pathogenic germline BRCA2 stop-gain mutation (rs80359031;
c.7988A > T; p.Glu2663Val) confirmed to predispose carriers to BRCA-associated cancers.
The somatic heterogeneity across the four tumour samples is striking (Figures 1 and 4A). Of the
78 overlapping SNVs (out of 24,195) present across all four samples, none had notable therapeutic
relevance. Phylogenetic reconstruction of this cancer’s evolution reveals distinct differences between
the left primary and the other three samples (Figure 4B). Notably, the left prostatic primary acquired a
somatic pathogenic BRCA2 stop-gain mutation ((c.6308C > G; p.Ser2103Ter), variant allele frequency
(VAF; 26%). Additionally, genes associated with several different growth signalling pathways, including
MAPK/ERK, TGF-β, PI3K and WNT, are impacted by SCNAs in the left primary but there are few
events in the other samples. No relevant SVs within the left lymph node were noted on WGM.
As expected with the combined germline and somatic BRCA2 mutations, there was a high rate of large
deletions in the left primary [10], including a 3Mb deletion overlapping multiple tumour suppressor
genes (TSGs) including BTG and DCN.
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Inter- and intra-patient heterogeneity have been well-described in PCa [13] and most recently in
multi-focal primary tumours [64], with significant therapeutic implications. The germline mutation not
only informs screening for secondary cancers and testing in relatives, BRCA2 mutations may also be
associated with a worse prognosis [65–69] and confer sensitivity to platinum-based chemotherapy [70]
and PARP-inhibitors [23,53]. However, there is increasing evidence that responses are markedly
improved with biallelic loss and many of the PARP inhibitor clinical trials have refined their inclusion
criteria to include only patients with biallelic alterations. Acquiring a somatic BRCA2 mutation in a
single primary tumour could result in a differential response to targeted therapies that would not be
predicted based on the typical single site sampling performed in clinical practice.
Aside from the germline BRCA2 mutation, there is no unifying therapeutically relevant event
across all four samples. Having had short-term ADT preoperatively, losses in NCOR1 and NCOR2 as
well as other SCNAs associated with CRPC within the left primary raise the possibility that early ADT
resistance is developing after minimal treatment.
In practice, knowledge of this patient’s genomic landscape at baseline may have prompted his
treating clinician to escalate his treatment with combination systemic therapy such as the rucaparib
arm of the STAMPEDE trial. The loss of NCOR1 and NCOR2 and the poorer prognosis conferred by his
TP53 and BRCA2 status represent potential indications for early chemohormonal therapy (ADT with
docetaxel chemotherapy) despite him having low-volume, node only metastases [3,4,46,71]. BRCA2
alterations may also sensitize this patient to radiotherapy due to impaired DDR. Therefore, had his
genomic data been available early, an upfront strategy with radiotherapy to his primary in combination
with ADT and docetaxel may have been used. At progression, he may be considered for a clinical
trial with a PARP inhibitor, potentially in combination with another agent given his somatic BRCA2
discordance. A metastatic biopsy at a site of progression could prove useful in determining whether
new sites of disease harbour the somatic BRCA2 alteration.
2.3. Primary Prostate Samples with Relapse Post Radical Prostatectomy: 12543, 5545, 5684, and 13179
At the time of surgery, none of these cases had evidence of metastatic disease on staging scans.
All men subsequently relapsed with incurable disease, including bone metastases (5545, 5684 and 13179)
and persistent BCR with eventual CRPC (12543). While TMBs were similar (range 1.4–1.9), there was
more marked variability in their PGAs (range 3.1–26%). Genomic alterations with patient-specific
relevance are summarized in Figure 5.
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2.3.1. Case 12543: Left Prostate Tumour Core Biopsy
This patient’s tumour is characterized by KMT2C mutation, copy number losses (supported by
large deletion) in PTEN and FOXP1 and an ETV1-ACSL3 fusion. ETV1-ACSL3 fusion may account for
this patient’s prolonged ADT sensitivity (no evidence of metastatic disease following 10 years on ADT
for BCR). ACSL3 is an androgen responsive gene and thus, this fusion may lead to a strong reliance on
androgen signalling [72]. Despite PTEN loss, loss of FOXP1 may restore androgen receptor signalling,
further enhancing this patient’s response to ADT despite the PTEN loss [73]. At development of CRPC,
this reliance on AR signalling may be exploited further with the addition of a novel ASI to his ADT,
rather than docetaxel.
2.3.2. Case 5545: Left Prostate Tumour Core Biopsy
This case is characterized by a deleterious somatic SPOPmissense variant (rs193921065, c.399C > G;
p.Phe133Leu; VAF 44%) [7] and a large hemizygous deletion encompassing CHD1. We also predict the
LRB1B mutation (c.3178A > G; p.Cys1060Arg) to be deleterious. Notable copy number losses include
TP53BP1 and the TSGRB1 and the DDR genesFANCA andPPP2R2A, while a deletion overlappedLRP1B.
Unique to WGM, we identified a large deletion involving FILIP1L, a gene commonly hypermethylated
in PCa [74].
Point mutations in SPOP occur in approximately 11% of primary PCas [7] and are commonly
associated with CHD1 loss [75]. This combination of alterations is associated with increased abiraterone
sensitivity in CRPC [76]. These tumours are also characterized by increased genomic instability due
to error-prone double-strand DNA break repair, which results in more SVs, as seen in this case, and
potential vulnerability to DNA damaging treatment such as irradiation, PARP inhibition and platinum
chemotherapy [77]. Loss of FANCA, a gene involved in homologous recombination, may also sensitise
this cancer to PARP inhibition. A recent retrospective study found that LRP1B alterations may predict
for sensitivity to pembrolizumab [78].
SPOP/CHD1 co-altered clones persist across the disease spectrum in studies of serial patient
samples [76]. Therefore, knowledge of this case’s genomic data from radical prostatectomy would
lead to a preference for abiraterone over docetaxel at development of CRPC. These alterations may
also increase his responsiveness to PARP inhibition, though evidence is limited and preclinical models
have shown that this vulnerability is reliant on elevated 53BP1 protein levels [77] and so the copy
number loss in TP53BP1 may counteract this vulnerability. This combination of alterations highlights
the importance of understanding the entire genomic landscape in an individual.
2.3.3. Case 5684: Right Prostate Tumour Core Biopsy
This case harbours a small frameshift deletion in TP53 between exons 11 and 12, in addition to
heterozygous copy number loss and a deletion on SV analysis. He also presented with SCNA in CDH1
and alterations in other DDR genes including: an SNV in CDK12 and SCNAs in PPP2R2A and FANCA.
Losses in genes affecting proliferative pathways include those in PIK3R1, the loss of which activates
the PI3K pathway [79] and MAP3K1, which is associated with MEK signalling [80]. The inclusion
of WGM for 5684 revealed a large insertion overlapping SPOCK1, which encodes a protein found to
promote tumorigenesis and metastases in PCa [81]. WGM also identified an insertion in CREBBP, a
coactivator of AR that is usually overexpressed in CRPC and the upregulation of which is associated
with ADT resistance [82].
TP53 loss confers a worse prognosis and improved outcomes with chemotherapy compared to
novel ASI agents [62]. Knowledge of his primary tumour TP53 status may have guided ordering
of therapies with a preference for chemotherapy, particularly upon progression to CRPC. A study
of co-targeting PARP and Wee1 kinase with olaparib and AZD1775 is currently underway for TP53
mutated solid tumours (NCT02576444). The losses in PIK3R1 and MAP3K1 may confer sensitivity
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to PI3K and MEK inhibitors respectively though these agents would only be used on a suitable
clinical trial.
2.3.4. Case 13179: Right Prostate Tumour Core Biopsy
This TMPRSS2-ERG positive tumour is characterised by a high PGA at 26%, pathogenic somatic
SNV in TP53 (rs28934575, c.733G > A; p.Gly245Ser), as well as copy number loss of PTEN. Additional
losses in MAP3K1, PIK3R1 and TP53 were observed, along with somatic alterations in the MAPK and
PI3K pathways (Figure 5).
Co-loss of TP53 and PTEN is associated with more aggressive disease, which is consistent with this
patient’s clinical course. Knowledge of these molecular features may have triggered more aggressive
treatment upfront. Within current treatment paradigms, this may have included radiotherapy with
ADT and docetaxel [5,71]. Additionally, the number of alterations in multiple targetable pathways,
particularly PI3K (PI3K/AKT inhibitors) and MAPK/ERK (BRAF/MEK inhibitors), highlights the
need to contextualise genomic events rather than viewing them in isolation. It is likely that this
patient’s treatment regimen would need to involve a tailored combination strategy if a targeted,
precision-medicine approach was to be considered.
2.4. Bone Metastatic Samples: 147, A153, PCSD13 and 1135
Sampling for genomic analyses occurred at bone biopsy. Patients 147 and A153 had not
yet had systemic therapy, while 1135 had CRPC, having commenced intermittent ADT for BCR
3 years postoperatively. PCSD13 presented with de novo metastatic disease manifesting as hip pain.
Investigations revealed multiple bone metastases and an elevated PSA. Selected genomic events are
summarized in Figure 6.
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2.4.1. Case 147: Biopsy Left Pubic Bone Corresponding to Sclerotic Region on Imaging
This case did not have any relevant somatic SNVs or WGS-identified SVs. SCNAs included gains
in BRAF, AHNAK and BRD4.
It is unknown, yet unlikely, whether the copy number gain in BRAF would be sufficient to sensitize
the patient to BRAF inhibition. The low level of relevant alterations in this case may explain his less
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aggressive disease course with a late clinical relapse (10 years post prostatectomy). The gains in BRD4
and AHNAK may have contributed to metastasis formation: BRD4, part of the Bromodomain and
Extraterminal (BET) protein family, regulates tumour cell migration and invasion through transcription
of AHNAK [83]. Small molecule BRD4-selective degraders inhibit metastatic potential in PCa cell
lines and a Phase I clinical trial of birabresib which included CRPC patients has been completed [84].
BRD4 is also involved in the non-homologous end joining (NHEJ) DDR pathway and higher protein
levels from pre-treatment biopsies are associated with poor outcomes following radical radiotherapy
in localized disease [85].
2.4.2. Case A153: Biopsy Right Iliac Crest Corresponding to Metastatic Deposit on Imaging
This TMPRSS2-ERG positive metastatic tumour harboured a pathogenic TP53 mutation
(rs121912656, c.734G > T; p.Gly245Val) and a high PGA (25.5%). SCNAs include losses in APC,
PTEN, CHD1, BRCA2, FANCA, PIK3R1 and LRP1B. A complex SV on chromosome 5 encompassing
PPAP2A, PDE4D, MAP3K1 and IL6ST, was previously associated with a worse prognosis [8].
TP53 loss is associated with a worse prognosis and decreased response to abiraterone in CRPC.
APC loss, through its activation of Wnt signalling, may promote ASI resistance [32,62]. These two
features would make docetaxel a better option than an ASI in the first instance for this patient at
metastatic relapse. BRCA2 and FANCA alterations were predictive for sensitivity to olaparib in the
TOPARP studies [23,53] and, as previously discussed, PTEN and CDH1 losses may sensitize this patient
to PARP inhibition [54,77].
2.4.3. Case PCSD13: Biopsy Left Femur during Total Hip Replacement for Pathological Fracture
PCSD13 presented with a pathogenic germline IDH2 mutation (rs121913502, c.419G > A;
p.Arg140Gln). Reported to have an allele frequency of 0.00003 in The Genome Aggregation Database
(gnomAD) [86], while associated with several other cancers, this mutation has not yet been reported
in PCa [87]. In addition to an SNV in AKT1, there is a copy number gain in this gene. There are
losses in the DDR genes CDK12 and MLH1, and SVs also overlap multiple DDR genes. The COSMIC
Mutational Signatures in this case show a subclonal increase in the proportion of Signature 3, whereas
the majority of the other samples showed a decrease in this signature, which is associated with failure
of double-strand DNA repair (Figure 2B).
The AKT1 alterations may have contributed to his early ADT resistance (within 3 months of
starting ADT) and confer sensitivity to AKT inhibitors [19]. These alterations could influence decisions
on escalating ADT treatment with the addition of abiraterone, an androgen targeting drug, or docetaxel.
However, the crosstalk between AR and PI3K/AKT signalling is well-established, [88,89] and additional
pressure on the androgen axis in the context of an AKT1 amplification may only drive further growth
via the PI3K pathway. In the absence of a clinical trial with an AKT inhibitor, the addition of docetaxel
rather than an AR targeting agent may have been more prudent. Immune checkpoint inhibition may
have been another treatment option for this patient with his CDK12 and MLH1 SCNAs. This patient
succumbed to his cancer shortly after developing CRPC.
2.4.4. Case 1135: Biopsy Right Posterior Iliac Crest Corresponding to Metastatic Deposit on Imaging
Despite having CRPC at the time of biopsy, case 1135 had very few alterations of interest with
a TMB of 0.73 and PGA of 3.1%. This tumour contained SNVs in KMT2C and IDH2 (rs121913502,
c.419G > A; p.Arg140Gln) and SCNAs in BCOR, NCOA7, and NOTCH2. No significant SVs were
identified with WGS but a homozygous deletion overlapping TNS3 was identified using WGM.
The somatic SNV in IDH2 is the same as the germline alteration seen in PCSD13 that has not
been reported in PCa. It is unclear whether this mutation would drive the progression of this patient’s
cancer and if IDH inhibitor therapy, used to treat IDH-mutant AML, would be relevant. Based on
preclinical studies, KMT2C alterations may confer sensitivity to PARP inhibition via its effects on the
epigenetic status and expression of DDR genes. However, alterations in KMT2C are frequent in PCa [7]
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and responses to PARP inhibition only occur in a small proportion of patients [23]; therefore, it is
unlikely this SNV alone will be enough to predict sensitivity to PARP monotherapy. ATRX is a DDR
pathway gene while BCOR, NCOA7 and NOTCH2 are involved in androgen signalling. However,
these alterations do not yet have any targeted therapeutic strategies for CRPC. While the impact of
the deletion in TNS3 is again unclear, it is noted that Tensins are a family of scaffolding proteins
that regulate cell motility and growth and TNS3 in involved in MET signalling [90], a target of the
tyrosine kinase inhibiting drug, cabozantinib. Overall, though this case’s alterations do not yet have
any therapeutic relevance, the knowledge of molecular features in PCa is rapidly evolving and future
findings may bring useful drugs to light.
2.5. Case 80002: Core Biopsy at Resection of Brain Metastasis
Patient 80002 presented with a solitary brain metastasis that was surgically resected. His PSA was
elevated and morphology of the tumour specimen was consistent with an adenocarcinoma of prostatic
origin; immunohistochemistry (IHC) markers for neuroendocrine differentiation were negative.
The relevant genomic features of this TMPRSS2-ERG fusion positive case are summarized in
Figure 7 and include: TP53 mutation (rs1057519999, c.716A > C; p.Asn239Thr) and SCNAs in CDK12,
RAD51C, RNF43, TP53, and BRAF. This tumour presented with a high rate of SVs, including a
large deletion overlapping TP53, a partial deletion of LRP1B, and an interchromosomal translocation
involving CTNNA1, the downregulation of which is associated with a worse prognosis in PCa [91].
Using our WGM approach, we identified additional large heterozygous deletions. Two overlap TSGs
including TP53 and KCTD11, and another overlaps with TBX3 [92] and NRF2. NRF2 has been shown to
suppress PCa cell mitosis and migration [93,94]. Another large deletion on chromosome 2 overlapped
HOXD10 and HOXD3. Decreased HOXD10 expression promotes an aggressive phenotype in PCa in
knockdown mice, as well on retrospective review of clinical outcomes [95] and HOXD3 methylation
predicts earlier BCR [96].
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Although COSMIC Mutational Signatures 1, 5, 8 and 9 are present, Signatures 17 and 18 contribute
>5% each. Signature 18 may be associated with failure of base excision repair [97] and enriched in
metastatic PCa [8]. Signature 17, predominantly found in gastric and oesophageal cancers, has been
shown to co-occur with Signature 18 in mouse models of these cancers and this signature may be a
by-product of oxidative damage [98,99].
Brain metastases are uncommon in prostate adenocarcinoma and tend to occur in cases with
neuroendocrine differentiation [100]. However, gains in FOXA1, as seen in this case, are thought to
protect against neuroendocrine trans-differentiation [101] and the TMPRSS2-ERG fusion supports the
prostatic origin. This patient has a number of targets impacting androgen signalling, DDR and MAPK
pathways. His clinical presentation would already support aggressive therapy with combination
therapy and his genomic data include several poor prognostic features. The partial LRP1B deletion
may produce sensitivity to pembrolizumab but the evidence for this is limited so this should only be
considered as part of a clinical trial potentially upfront with docetaxel or later in his clinical course
at development of CRPC. KCTD11 is a negative regulator of hedgehog pathway signalling [102] and
therefore its loss, identified using WGM, may increase signalling and imply this tumour would be
sensitive to pathway inhibitors.
3. Materials and Methods
Included cases had adenocarcinoma of prostatic origin and were selected based on availability
of tissue and matched blood specimens and micro- or overt metastatic disease either at the time of
sampling or subsequent to radical prostatectomy. Patients sampled at the time of radical prostatectomy
(primary tissue) had either pathologically confirmed lymph node metastases (19011, 19145, 19260,
19651) at diagnosis or subsequent metastatic relapse post-surgery (5545, 5684, 12543, 13179). Patients
recruited at presentation of distant metastases had bone (1135, 147, A153, PCSD13) or brain (80002)
tissue sampled.
All samples were obtained with written informed consent, as per the study approval granted
from the St. Vincent’s Human Research Ethics Committee (HREC), SVH/12/231 and HREC/12/SVH/323,
Melbourne Health Human Research Ethics Committee HREC/12/MH/272 and Epworth Health 55512,
or University of California Institute Review Board (IRB) approval 090401. Samples were shipped to the
Garvan Institute of Medical Research in accordance with institutional Material Transfer Agreements
(MTAs), and genomic screening and analysis were performed in accordance with approval granted by
St. Vincent’s Hospital HREC SVH/15/227 and governance review authorisation granted for human
research at the Garvan Institute of Medical Research GHRP1522.
Primary tumour samples were collected at the time of radical prostatectomy and two core biopsies
were taken from the prostate regions with cancer on preoperative biopsy. Lymph node tissue was
collected at the time of radical prostatectomy from nodal masses with palpable tumour. Metastatic
samples were obtained by image guided biopsy or at surgical resection (80002, PCSD13). All tissue
samples were snap frozen. The presence of prostate cancer and its location within the samples was
confirmed by a pathologist prior to dissection for DNA extraction. DNA was extracted from tissue and
buffy coat or whole blood using one of two commercially available kits: the DNeasy blood and tissue
kit protocol (Qiagen, Maryland), or for high molecular weight (HMW) DNA, the Bionano Prep Frozen
Human Blood and Animal Tissue DNA isolation protocols (Bionano Genomics, San Diego document
#30246 and #30077).
Demographic, clinical and pathological data were collected for each patient and are summarised
in Figure 1 and Table 1. The median patient age at the time of PCa diagnosis was 65 years (range 51–77).
The median time to biochemical recurrence (BCR) for those that underwent definitive first-line treatment
and subsequently relapsed (n = 8) was 43.5 months (range 6–93); six of these patients relapsed with
metastatic disease detectable on standard imaging at a median time of 86.5 months from initial diagnosis
(range 24–120).
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3.1. Whole Genome Sequencing (WGS)
DNA from tumour and matched blood underwent 2 × 150 bp sequencing on an Illumina
HiSeq X Ten instrument (Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical
Research) averaging over 80× and 40× coverage, respectively. Read adapters were trimmed using
Illumina’s Bcl2fastq Conversion software (Illumina) and filtered to remove low quality bases (<Q15),
short reads (<70 bp) and missing read pairs using cutadapt v1.9 [103]. Remaining reads were
aligned to GRCh38 reference using bwa-mem v0.7.15 [104], with the ALT-aware mode. Alignment
statistics were calculated using QualiMap v2.1.3 [105] and stromal contamination was calculated
using Sequenza [106]. Sequencing statistics are summarized in Table S2. The sequencing data for the
tumor and blood samples are available in the NCBI BioSample database under the following range of
accessions: SAMN14209964–SAMN14209992.
3.2. WGS Variant Calling
The GATK pipeline version 3.5-0 was used for small variant calling [107]. We defined small
variants as single nucleotide variants (SNVs) and insertions or deletions (indels) ≤ 50 bases and
structural variants (SVs) as events ≥ 50 bases. Analysis-ready alignment per sample was called for
SNVs and indels (GVCF mode) using GATK HaplotypeCaller (GVCF mode; [107]). Per-sample GVCFs
were used for joint genotyping across genomes (GATK GenotypeGVCFs). Joint-called SNVs and
indels were filtered via machine learning variant quality score recalibration and passed loci were
kept. High-confidence somatic variants were called for each tumour-blood pair using MuTect2 [108].
A combination of GRIDSS and LUMPY was used for the detection of germline and somatic SVs [109,110];
potentially relevant SVs were manually inspected using Integrative Genomics Viewer (IGV) [111].
For somatic copy number alterations (SCNAs), binned copy number and segmentation profiles were
determined using the copy number calling pipeline in the CNVkit package; gains (CN > 2) and losses
(CN < 2) were assessed on calls adjusted for tumour purity [112].
3.3. WGS Variant Annotation
Germline and somatic SNVs and indels were annotated using Annovar [113] and pathogenic
variants were manually inspected using IGV [111]. Missense mutations were further classified as
potential oncogenic drivers using CanDrA [114] with PCa-specific databases.
The 30 SNV-derived Catalogue Of Somatic Mutations In Cancer (COSMIC) Mutational Signatures
were annotated using the SomaticSignatures package in R [115]. Estimation of clonality and clonal
segregation of somatic mutations were computed using PhyloWGS [116] and TITAN program [117].
3.4. Tumour Mutational Burden and Percentage Genome Alteration
TMB was calculated by counting the total number of small somatic mutations and dividing by
genome size (3088 megabases (Mb)). PGA was calculated based on the cumulative number of base
pairs altered for each gain or loss in the autosome (Chromosomes 1–22) per patient divided by the
reference autosomal genome size (2875 Mb).
3.5. Whole Genome Optical Mapping
HMW DNA were fluorescently-labelled using either nicking enzyme Nt.BspQI (New England
Biolabs) or non-nicking enzyme DLE-1 (BNG, Part #20351), according to the Bionano Prep Labeling
NLRS Protocol (Document #30024) or Direct Label & Stain protocol (Document #30206), respectively.
Samples prepared with BspQI (1135, 147, A153) were imaged using the Bionano Genomics (BNG) Irys
system (San Diego, CA), while those prepared with DLE-1 (80002, 19651, 12543, 13179, 5545, 5684) were
imaged using the BNG Saphyr system, to generate single molecule optical maps.
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De novo assembly of single molecules into consensus genome maps was performed with the
Bionano Solve (≥v3.2) software with aligner RefAligner (≥7437) [118–120]. Custom sets of parameters
were used for this purpose and are included as File S1.
3.6. WGM Derived Genomic Rearrangements
SVs were identified relative to the human reference genome, GRCh38, whose genome maps were
bioinformatically deduced based on predicted Nt.BspQI (GCTCTTCN) or DLE-1 (CTTAAG) motif
sites. SV detection was performed as part of the Bionano Solve pipeline. Details of the underlying
algorithm are described in the software’s accompanying documentation (Document # 30110B).
3.7. WGM Derived Data Filtering
Filtering steps were performed on the resulting SVs. First, SVs that did not pass the Bionano
recommended confidence level for the corresponding SV type were excluded; that is, all SVs other
than inversion must have confidence > 0.1 and both breakpoints of an inversion event must have
confidence > 0.01. Second, only rare SVs were included, defined as being observed in < 10% of a
cohort of ~150 “normal” samples provided by Bionano [121]. Finally, “somatic” SVs were identified
as those supported by a minimum of yt molecules in the tumour sample but not observed in more
than yn molecules in the matching-normal sample, where y = −0.3 + 0.13 * x and x being the effective
coverage of the corresponding sample. This formula is recommended by Bionano as detailed in
their Variant Annotation Pipeline v1.0 (BNG document # 30190). The minimum coverage cut-offs for
somatic SV calling are summarized in Table S8. The WGM data are available at the following Doi:
10.25833/7wqs-gb12 [122].
3.8. Generation of a Prostate Cancer-Related Gene List
In addition to identifying annotated pathogenic and likely pathogenic alterations as well as the
top genes affected by SCNAs, we reviewed alterations involving potential PCa driver genes and
non-coding events associated with prostate cancer. A list of 159 PCa-associated genes was compiled
from recent studies that identified recurrently mutated genes in primary and metastatic samples
(Table S7) [6–9]. The list included commonly altered genes with potential functional relevance from
The Cancer Genome Atlas (TCGA) primary PCa data [7,123], potential driver genes identified in
primary and metastatic samples by Wedge et al. [8] and genes recurrently mutated in metastatic disease
as identified by Robinson et al. [6] and Armenia et al. [9]. A list of non-coding events was compiled
from recent published data (Table 4).
3.9. Other Analyses
The full list of binding clusters of 340 TFs compiled by the ENCODE project was obtained from
the University of California Santa Cruz data repository (encRegTfbsClistered table; last updated
16 May 2019) and examined for somatic variants using a custom R script. Somatic variants within
AR binding sites were evaluated against published putative binding sites observed in the LNCaP
prostate cancer cell line (NCBI Gene Expression Omnibus accession GSE83860; [33]). The Circos plots
in Figures 3–7 were generated using the CIRCOS software (v0.69-6) [124] based on SNV/indel data from
MUTECT, copy number data from CNVkit, and SV data from GRIDSS. Phylogenetic reconstruction of
tumour evolution for patient 19651 was performed using phyloWGS [116] based on SNV/indel data
from MUTECT and copy number data from TITAN. Analyses of COSMIC Mutational Signature [125]
clonal evolution was performed using the R package Palimpsest v1 [126] which utilized SNV data
from MUTECT for estimates of mutation signature and SNV allele frequency data from MUTECT
along with copy number segmentation data from Sequenza [106] for estimates of clonality.
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4. Discussion
These real-world clinical cases demonstrate that clinically relevant mutations occur even in
treatment-naïve patients across the spectrum of disease from high-risk primaries to metastatic cases.
While the pathways impacted in these cases align with those identified in larger scale genomic studies,
the coexistence of multiple alterations has not been explored. These findings raise several points.
Firstly, studies of neoadjuvant or adjuvant docetaxel in men with high-risk localized disease
undertaking radical prostatectomy or definitive radiotherapy with ADT have had conflicting results [4,
46,71] but a subgroup of men appear to benefit. Poor prognostic genomic findings, such as TP53
deletions or deleterious BRCA2 alterations at baseline may be useful in selecting men for additional
treatment. Similarly, not all men require escalated treatment beyond ADT for HSPC but biomarkers
to guide treatment selection remain limited. The findings of TP53 and/or Wnt pathway activating
alterations in 5/8 (63%) of our primary samples highlight a potential biomarker for selecting men that
should be considered for escalated therapy, preferably with docetaxel rather than a novel ASI [32,62,127].
Though speculative in the hormone sensitive setting, there is mounting evidence these alterations
could be useful in guiding treatment selection in CRPC. Secondly, we observed events in minimally
treated patients, such as NCOR1 and NCOR2 losses, that may be associated with ADT resistance.
These alterations again may identify patients at risk for early development of CRPC who may
need escalated therapy upfront. Thirdly, pathway mutations typically enriched in metastatic CRPC,
particularly PI3K and MAPK pathway SCNAs, were frequently seen in our patients and represent
potential targets for neoadjuvant intervention in high risk localized and/or de novo metastatic HSPC
clinical trials.
The addition of WGM in our study did not identify a current therapeutic target but it did identify
SVs impacting oncogenic and tumour suppressing genes that were not identified by using WGS alone.
Though we did identify non-coding events affecting the promoters, enhancers and TF binding sites of
relevant genes, their therapeutic relevance has yet to be elucidated. However, as WGS and WGM data
accumulate and annotations improve, we may find new relevant mutations and begin to understand
how they may be integrated into clinical practice. Additionally, the use of complementary genomic
technologies such as RNA-sequencing and chromatin immunoprecipitation sequencing may improve
our ability to translate genomic data into real-world clinical decision-making.
In this retrospective study, we assess the current status of genome profiling, specifically WGS and
WGM, to inform decision-making for 13 patients presenting with metastatic PCa. Our findings suggest
that, despite being a cancer associated with a low TMB, individual PCas can harbour complex series of
mutations affecting multiple growth pathways. Therefore, the precision medicine model of identifying
one target to treat is unlikely to succeed. Given its heterogeneity and despite comprising only a very
small fraction of the I-PREDICT study cohort [128], PCa may be the ideal cancer to test the paradigm
of using genomics to identify and treat multiple targets simultaneously.
5. Conclusions
Our analyses demonstrate that whole genomic interrogation of PCas may provide invaluable
information at any stage of the disease. Most of our cases had alterations affecting multiple signalling
pathways highlighting the utility of a comprehensive molecular assessment in tailoring treatment
strategies to an individual. Moreover, WGM identified SVs disrupting prostate cancer relevant genes
that were not apparent on our WGS analyses. Many non-coding and WGM events were identified but
their therapeutic relevance is yet to be established. Though these data add to our current knowledge,
further research is needed, potentially integrating additional genomic technologies, to identify new
treatment targets and predictive biomarkers. While several potential biomarkers that may influence
treatment decisions were found in these patients, most have yet to be validated in prospective
clinical trials.
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